Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.57 |
| ▸ | IDO1 | P14902 | 2/20 | 0.57 |
| ▸ | MMP2 | P08253 | 5/20 | 0.57 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.50 |
| ▸ | KDM6B | O15054 | 1/20 | 0.50 |
| ▸ | KDM6A | O15550 | 1/20 | 0.50 |
| ▸ | TET3 | O43151 | 1/20 | 0.50 |
| ▸ | KDM4A | O75164 | 1/20 | 0.50 |
| ▸ | KDM4B | O94953 | 1/20 | 0.50 |
| ▸ | KDM5C | P41229 | 1/20 | 0.50 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 0.50 |
| ▸ | TET2 | Q6N021 | 1/20 | 0.50 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.50 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 0.50 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.50 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.50 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.50 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.50 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7032474 | 0.81 | IDO1 (0.61) | KDM4EIDO1MMP2PDE4DL3MBTL1 | |
| SCHEMBL6030652 | 0.77 | ALDH1A1 (0.74) | KDM4EL3MBTL1RAB9ALMNAHTT | |
| SCHEMBL13656141 | 0.76 | IDO1 (0.59) | KDM4EIDO1MMP2PDE4DL3MBTL1 | |
| SCHEMBL24081122 | 0.75 | IDO1 (0.66) | KDM4EIDO1MMP2L3MBTL1KDM6B | |
| SCHEMBL4025039 | 0.75 | TDP1 (0.73) | KDM4ELMNAHTTSMN1; SMN2GAA | |
| SCHEMBL12835259 | 0.74 | TDP1 (0.56) | KDM4EIDO1MMP2PDE4DL3MBTL1 | |
| SCHEMBL1133560 | 0.74 | KDM4E (0.54) | KDM4EIDO1MMP2PDE4DL3MBTL1 | |
| SCHEMBL16525559 | 0.74 | PDE4D (0.66) | KDM4EIDO1PDE4DL3MBTL1NPC1 | |
| SCHEMBL14130573 | 0.73 | IDO1 (0.64) | KDM4EIDO1MMP2L3MBTL1KDM6B | |
| SCHEMBL22705016 | 0.73 | IDO1 (0.64) | KDM4EIDO1MMP2L3MBTL1KDM6B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | ABSOLUTE SCIENCE, INC. (US) | 2011-08-04 | — | — | US | disclosed |
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2011-02-10 | — | — | US | disclosed |
| WO-2010033360-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | 1/3 ABSOLUTE SCIENCE, INC. (US) | 2010-03-25 | — | — | WO | disclosed |
| WO-2009045761-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | ABSOLUTE SCIENCE, INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034521-A1 | COMPOUNDS AND METHODS FOR TREATING ZINC MATRIX METALLOPROTEASE DEPENDENT DISEASES | MMP7, MMP3, MMP9 | KDM4E 1274/4885IDO1 616/4885MMP2 15/4885 |
| US-20110190285-A1 | METHODS OF TREATING A BOTULINUM TOXIN RELATED CONDITION IN A SUBJECT | NPY5R, RAC3, CPA3 | KDM4E 1963/4885IDO1 555/4885MMP2 17/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.